Irida Kastrati

Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.

Activation of estrogen receptor-mediated gene transcription by the equine estrogen metabolite, 4-methoxyequilenin, in human breast cancer cells.

Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.

Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms.

Estrogenic activity of the equine estrogen metabolite, 4-methoxyequilenin.

Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators.

Estrogen-induced apoptosis of breast epithelial cells is blocked by NO/cGMP and mediated by extranuclear estrogen receptors.

Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells.

NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms.

A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties.

Dimethyl Fumarate Inhibits the Nuclear Factor κB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein.

Full antagonism of the estrogen receptor without a prototypical ligand side chain.